S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The Collapse of 2022 Has Begun (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The Collapse of 2022 Has Begun (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The Collapse of 2022 Has Begun (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The Collapse of 2022 Has Begun (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:ADAP

Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News

$1.08
+0.01 (+0.94%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.01
$1.09
50-Day Range
$1.06
$2.41
52-Week Range
$1.01
$5.95
Volume
314,129 shs
Average Volume
388,619 shs
Market Capitalization
$175.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Adaptimmune Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
179.1% Upside
$3.00 Price Target
Short Interest
Bearish
2.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Adaptimmune Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$13,590 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

504th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

80th out of 171 stocks

ADAP stock logo

About Adaptimmune Therapeutics (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Stock News Headlines

Mizuho Securities Reaffirms Their Hold Rating on Incyte (INCY)
Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Why Adaptimmune Therapeutics Stock Is Popping Today
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Company Calendar

Last Earnings
8/04/2022
Today
10/02/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAP
Employees
494
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+179.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-158,090,000.00
Net Margins
-1,500.43%
Pretax Margin
-1,487.45%

Debt

Sales & Book Value

Annual Sales
$6.15 million
Book Value
$1.32 per share

Miscellaneous

Free Float
134,993,000
Market Cap
$175.62 million
Optionable
Optionable
Beta
1.76

Key Executives

  • Mr. Adrian G. RawcliffeMr. Adrian G. Rawcliffe (Age 50)
    CEO, Principal Accounting Officer & Director
    Comp: $1.01M
  • Dr. Helen Katrina Tayton-Martin MBA (Age 55)
    Ph.D., Co-Founder & Chief Bus. Officer
    Comp: $709.84k
  • Mr. Gavin Hilary James Wood BA (Hons) (Age 52)
    ACA, Chief Financial Officer
    Comp: $686.96k
  • Mr. William C. Bertrand Jr.Mr. William C. Bertrand Jr. (Age 57)
    Esq., J.D., Chief Operating Officer
    Comp: $687.09k
  • Mr. John LungerMr. John Lunger (Age 53)
    Chief Patient Supply Officer
    Comp: $645.91k
  • Ms. Joanna Brewer Ph.D.
    Chief Scientific Officer
  • Dr. Juli P. Miller Ph.D.
    VP of Investor Relations
  • Ms. Kerry Sharp
    Sr. VP & Gen. Council
  • Ms. Margaret Henry
    Head of PR & Company Sec.
  • Mr. Sébastien Desprez
    VP of Communications & Corp. Affairs













ADAP Stock - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADAP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price forecast for 2022?

1 equities research analysts have issued 12 month price targets for Adaptimmune Therapeutics' stock. Their ADAP share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 179.1% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2022?

Adaptimmune Therapeutics' stock was trading at $3.75 at the beginning of the year. Since then, ADAP stock has decreased by 71.3% and is now trading at $1.0750.
View the best growth stocks for 2022 here
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28). The biotechnology company had revenue of $5.54 million for the quarter, compared to the consensus estimate of $12.25 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 93.64% and a negative net margin of 1,500.43%.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $1.08.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $175.62 million and generates $6.15 million in revenue each year. The biotechnology company earns $-158,090,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

The company employs 494 workers across the globe.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001.

This page (NASDAQ:ADAP) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.